- 全部删除
您的购物车当前为空
EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].


为众多的药物研发团队赋能,
让新药发现更简单!
EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 2 mg | ¥ 1,670 | 5日内发货 | |
| 5 mg | ¥ 2,490 | 5日内发货 | |
| 25 mg | ¥ 8,930 | 6-8周 | |
| 50 mg | ¥ 11,600 | 6-8周 | |
| 100 mg | ¥ 16,600 | 6-8周 | |
| 1 mL x 10 mM (in DMSO) | ¥ 2,730 | 5日内发货 |
EMI48 相关产品
| 产品描述 | EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1]. |
| 体外活性 | EMI48 inhibits EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. EMI48 can be used in the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC) [1]. |
| 分子量 | 348.4 |
| 分子式 | C21H20N2O3 |
| CAS No. | 34564-13-1 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容